A phase II trial of gemcitabine and celecoxib as first-line treatment for patients with advanced metastatic pancreatic cancer.

Trial Profile

A phase II trial of gemcitabine and celecoxib as first-line treatment for patients with advanced metastatic pancreatic cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2012

At a glance

  • Drugs Celecoxib (Primary) ; Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 May 2010 Additional trial identifier [P30CA016672, MDA2003-0288] identified as reported by ClinicalTrials.gov.
    • 27 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top